Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease

Recruiting

• Conditions: infection caused by a nontuberculous mycobacteria; NTM disease; 10028440

• Registration Number: NL-OMON54666
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

- ATS/ERS/IDSA diagnostic criteria for NTM disease are met.

- The subject is eligible to start the guideline-recommended rifampicin-based
regimen according to the treating physician.

.- Age >= 18 years.

- Signed and dated patient informed consent

Exclusion Criteria

- ATS/ERS/IDSA diagnostic criteria for NTM disease are met.

- The subject is eligible to start the guideline-recommended rifampicin-based
regimen according to the treating physician.

- Age >= 18 years.

- Signed and dated patient informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Total exposure (area under the concentration versus time curve from T=0 up to<br /><br>24 hours, after a 5-day dosing periode of minocycline; AUC0-24h), pre-dose<br /><br>concentration (Ctrough) and peak serum concentration (Cmax) of minocycline<br /><br>before and after start of a rifampicin containing regimen</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Pharmacokinetic parameters of rifampicin.</p><br>